TUESDAY, 1 JuLY

Program subject to change.

8:30 - 9:25 | Workshops


Workshop 1 - KSCPT and EACPT Workshop 1: Model-informed precision dosing in pediatrics – Focus on cytotoxic agents

8:30 - 8:45The long journey to develop Model-Informed Precision Dosing of Busulfan in Korean pediatric patients
SeungHwan Lee, Seoul National University Hospital, Seoul, Korea

8:50 - 9:05Multi-center Studies on Busulfan Precision Dosing in Pediatric Patients
Eline Muilwijk, Prinses Máxima Centrum, Utrecht, The Netherlands

9:10 - 9:25Carboplatin TDM in childhood cancer patients
Gareth Veal, Newcastle University, Newcastle upon Tyne, United Kingdom

EUFEMED Workshop 2: Is there a need for more diversity in clinical drug development: Focus on early clinical trials.
Chairs: Jan de Hoon, University & University Hospitals of Leuven, Leuven, Belgium

8:30 - 8:45The importance of diversity in global drug development: an overview
Yves Donazzolo, Eurofins, Lyon, France



8:45 - 9:05Diversity in First-in-Human clinical trials: did the healthy volunteer evolve over the last 10 years?
Thomas Lodeweyckx, SGS, Antwerp, Belgium



9:05 - 9:25Diversity in early-phase clinical trials: when to include patients?
Jan de Hoon, University & University Hospitals of Leuven, Leuven, Belgium



"Meet the Editors" Workshop
Chairs: Annikka Kalliokoski, Duodecim Medical Publications Ltd, Helsinki, Finland and Thomas Griesbacher, Medical University of Graz, Graz, Austria



8:30 - 9:30Presenters/Panelists
Ulf Simonsen, Editor-in-Chief, Basic & Clinical Pharmacology & Toxicology
Ann Daly, Senior Editor, British Journal of Clinical Pharmacology
Piet van der Graaf, Editor-in-Chief, Clinical Pharmacology & Therapeutics
Uwe Fuhr, Managing Editor, European Journal of Clinical Pharmacology


9:30 - 11:00 | Concurrent Sessions

Session A6: Pharmacoeconomics: economic aspects of pharmacotherapy
Chairs: Miia Turpeinen, University of Oulu, Oulu, Finland and Dinko Vitezic, University of Rijeka, Rijeka, Croatia


9:30 - 10:00Value based pricing of pharmaceuticals
David Webb, University of Edinburgh, Edinburgh, United Kingdom

10:00 - 10:30Innovative cost-sharing models
Zoltan Kalo, Semmelweis University, Budapest, Hungary

10:30 - 10:45Pharmacoeconomic evidence for disease-modifying therapies in spinal muscular atrophy: experience
from systematic and real-world data analyses (Abstract O036)
Andrej Belančić, Clinical Hospital Centre Rijeka & University of Rijeka, Faculty of Medicine, Rijeka, Croatia

10:45 - 11:00Deprescribing of high dose proton pump inhibitors (PPI’s) in an acute medical unit at NHS University
Hospitals of Liverpool Group (Abstract O037)
Rebecca Kuruvilla, NHS University Hospitals of Liverpool Group, Liverpool, United Kingdom

Session B8: Using routinely collected data to inform clinical pharmacology 
Chairs: Aleksi Tornio, University of Turku, Turku, Finland and Caridad Pontes, Universitat Autónoma de Barcelona, Barcelona, Spain

9:30 - 10:00Advances in pharmacoepidemiological analyses of real-world data 
Daniel Prieto-Alhambra, University of Oxford, Oxford, United Kingdom

10:00 - 10:30Strategic view on utilizing real-world data during drug development
Susana Perez-Gutthann, RTI Health Solutions, Barcelona, Catalonia, Spain

10:30 - 10:45Pseudo-worsening of renal function due to inhibition of renal creatinine secretion by oral antitumor
therapeutics – a real-world data analysis (Abstract O038)
Michael I. Sponfeldner, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

10:45 - 11:00Using pharmacovigilance data for signal detection of breast cancer resistance protein-mediated
drug interactions (Abstract O039)
Ronja Levomäki, Åbo Akademi University, Turku, Finland

Session C7: Global infectious disease threats
Chairs: Asko Järvinen, Helsinki University Hospital, Helsinki, Finland and Markus Zeitlinger, Medical University of Vienna, Vienna, Austria

9:30 - 10:00New drugs against multi-drug resistant (MDR) gram negative bacteria - are we loosing the battle
against the silent pandemia
Günther Weiss, Medical University of Innsbruck, Innsbruck, Austria

10:00 - 10:30New vaccine technologies as a response to Covid-19 and other infectious threats
Hanna Nohynek, Chair, Strategic Advisory Group of Experts on Immunization (SAGE),WHO, Finland

10:30 - 10:45Association of vancomycin pharmacokinetic/pharmacodynamic parameters with clinical outcomes in
patients with enterococcal bacteremia: a cohort study (Abstract O040)
Eda Kübra Sel, Dokuz Eylul University Faculty of Medicine Department of Medical Pharmacology, 
İzmir, Türkiye

10:45 - 11:00Genome-wide association study on inflammatory neuropathies and SARS-CoV2 vaccines
(Abstract O041)
Ilma Bertulyte, Department Of Medical Sciences, Clinical Pharmacology, Uppsala University,
Uppsala, Sweden
11:00 - 11:20 | Refreshment Break
11:20 - 12:00 | Keynote Lecture 3

Chair: Gerard Rongen, University of Nijmegen, Nijmegen, the Netherlands 
Topic to be announced
Speaker to be announced
12:00 - 13:30 | Lunch and Poster Viewing

      12:30 - 13:30       Presenters at posters P246-P268, P358-390, P430-P446
13:30 - 15:00 | Concurrent Sessions

ESPT & IUPHAR Session A7: Pharmacogenomics - challenges for implementation in different medical specialties
Chairs: Andrew Somogyi, University of Adelaide, Australia and Ann Daly, University of Newcastle, Newcastle, United Kingdom

13:30 - 14:00Implementing pharmacogenomics in psychiatry
Elvira Bramon, University College London, London, United Kingdom

14:00 - 14:30Implementing pharmacogenomics in oncology
Matthias Schwab, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

14:30 - 14:45Description of the prevalence of actionable pharmacogenetic variants in the Montreal Heart Institute
Hospital Cohort (Abstract O042)
Marc-Olivier Pilon, Université de Montréal, Montréal, Canada

14:45 - 15:00Pharmacogenetics of repaglinide, gemfibrozil, and their interaction: effects of SLCO1 and
CYP2C8 variants (Abstract O043)
Anssi Mykkänen, University Of Helsinki, Helsinki, Finland

Session B9: Advances in clinical trials methodology
Chairs: Maija Kaukonen, Medbase, Turku, Finland and Florian Naudet, University of Rennes, Rennes, France

13:30 - 14:00Routinely collected data (previously named as Real-World Evidence, RWE) integration in clinical trials
Lars G. Hemkens, University of Basel, Basel, Switzerland




14:00 - 14:30Innovative trial designs: Adaptive and platform trials
Mireille Muller, Novartis, Basel, Switzerland




14:30 - 14:45Personalized n-of-1 trials for statin intolerance (Abstract O044)
Michael Andersen, Department of Clinical Pharmacology, Copenhagen University
Hospital - Bispebjerg, Copenahgen, Denmark




14:45 - 15:00Pharmacokinetics and pharmacodynamics of AZD7798, a depleting antibody targeting
CCR9 +T cells in healthy participants and patients with Crohn’s disease (Abstract O045)
Anna Lundahl, Astrazeneca, Gothenburg, Sweden




Session C8: New strategies in treatment of cancer
Chairs: Olli Tenhunen, Finnish Medicines Agency Fimea and Oulu University Hospital, Oulu, Finland and Troels K. Bergmann, University of Southern Denmark, Odense, Denmark

13:30 - 14:00Repurposing of anti-cancer medicines
Kimmo Porkka, University of Helsinki, Helsinki, Finland




14:00 - 14:30Patient reported outcomes in cancer drug development
Sigrid Klaar, NDA Group - SSI Strateby, Uppsala, Sweden




14:30 - 14:45Higher ibrutinib exposure on day 1 is linked to more interruptions in the first four weeks (Abstract O046)
Cathrine Korsholm, Department of Clinical Pharmacology, Copenhagen University
Hospital - Bispebjerg, Copenhagen, Denmark




14:45 - 15:00Impact of thiazide and fluoropyrimidine interaction on myelotoxicity and other adverse
events: a retrospective cohort study (Abstract O047)
Gerard Ronda Roca, University Hospital Puerta de Hierro Majadahonda, Majadahonda (Madrid), Spain



15:00 - 16:00 | Closing Session and Farewells

Awards and closing ceremony (EACPT Chairs) 

Poster/Abstract presentation awards

Greetings from EACPT 

Future Congresses